On December 12, 2022 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, reported new data supporting the clinical potential of LYT-200, a fully human monoclonal antibody (mAb) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia (Press release, PureTech Health, DEC 12, 2022, View Source [SID1234625137]). The data were shared in a scientific poster presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) 64th Annual Meeting. LYT-200 is a therapeutic candidate targeting galectin-9, which is expressed by tumors and immune cells and plays a key role in cancer treatment resistance. It is also in development as a treatment for a range of cancer indications with otherwise poor survival rates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data we are presenting at ASH (Free ASH Whitepaper) add further support to the hypothesis that galectin-9 is an important therapeutic target for not just AML but multiple blood cancers, suggesting LYT-200 may be beneficial across a range of hematologic malignancies and underscores the potential of LYT-200 in an area with significant clinical need for novel treatment regimens," said Aleksandra Filipovic, M.D., Ph.D., Head of Oncology at PureTech. "The National Cancer Institute estimates that about 61,000 new cases of leukemia are diagnosed each year, including about 20,000 in AML. More than 50% of AML patients either don’t respond to initial treatment or experience relapse or death after responding to initial treatment, and have an approximately 12.6% five-year survival rate. The poor overall survival highlights the need for more effective therapies for patients with relapsed and refractory AML."
The ASH (Free ASH Whitepaper) poster evaluates galectin-9 expression and the effects of LYT-200 in multiple types of leukemia. Compared to healthy human peripheral blood mononuclear cells, where galectin-9 surface expression was low or absent, galectin-9 was highly expressed on the surface of all human blood cancer cells tested. Notably, surface expression of galectin-9 often exceeded that of the known inhibitory checkpoint proteins TIM-3 and PD-1.
In all models used, LYT-200 demonstrated significant anti-tumor activity and in addition to its established effects on the immune system in solid tumor models, it also notably induced direct apoptosis or cell death across all leukemia cell types. In a model assessing DNA damage in AML cells, LYT-200 significantly outperformed an anti-TIM3 antibody and had effects that were comparable to Venetoclax, an approved therapeutic for AML. The effects were greatest when both compounds were combined. The in vitro efficacy of LYT-200 against the leukemia subtypes also extended to in vivo survival benefit in both immunocompromised and immunocompetent patient-derived xenograft mouse models. In these models, LYT-200 outperformed chemotherapy and produced the greatest effect in combination.
Collectively, these new data support galectin-9 as a strong potential therapeutic target for a range of cancers. Based on this and other compelling preclinical data generated with LYT-200 in blood cancers, PureTech has initiated a clinical trial to evaluate LYT-200 as a single agent for the treatment of AML with results expected in 2023. PureTech has also completed the bi-monthly and weekly, monotherapy dose escalation portion of the Phase 1 program assessing the safety and tolerability of escalating doses of LYT-200 as a potential treatment of metastatic solid tumors. No dose-limiting toxicities were reported, and the full results will be presented in an upcoming scientific forum. The combination part of the Phase 1 trial in certain metastatic solid tumors with LYT-200 in combination with tislelizumab is expected to begin in the first quarter of 2023.
The scientific poster presented today is available at View Source
About LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody targeting a foundational immunosuppressive protein, galectin-9, for the potential treatment of solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer and cholangiocarcinoma, with otherwise poor survival rates. A wide variety of preclinical data supports the potential clinical efficacy of LYT-200 and the importance of galectin-9 as a target and suggests a potential opportunity for biomarker development. For example, PureTech has presented data demonstrating high expression of galectin-9 across various solid tumor types and blood cancers and has found in several cancers that galectin-9 levels correlate with shorter time to disease relapse and poor survival. LYT-200 is currently being evaluated in a Phase 1/2 adaptive design trial for the potential treatment of metastatic solid tumors and in a clinical trial for the potential treatment of AML.